dexmethylphenidate

Adjunctive therapy

Brands: FOCALIN, FOCALIN XR

Last reviewed 2025-12-29

Reviewed by PsychMed Editorial Team.

View details

Quick answers

What is dexmethylphenidate?
Dexmethylphenidate (brands Focalin and Focalin XR) is the d‑enantiomer of methylphenidate and is used as a first-line stimulant option for ADHD. In practice, it often achieves similar clinical effect at lower milligram doses than racemic methylphenidate.
What is FOCALIN?
FOCALIN is a brand name for dexmethylphenidate (other brands: FOCALIN XR).
What is FOCALIN (dexmethylphenidate) used for?
Label indications include: Attention-deficit/hyperactivity disorder (ADHD).
What drug class is FOCALIN (dexmethylphenidate)?
CNS stimulant; d-enantiomer of methylphenidate that inhibits dopamine and norepinephrine reuptake (DAT/NET).
What strengths does FOCALIN (dexmethylphenidate) come in?
Immediate-release tablets (often dosed twice daily).
What is the maximum recommended dose of FOCALIN (dexmethylphenidate)?
Maximum recommended dose depends on the specific product; labels specify maximums, and escalation beyond typical ranges usually prompts reassessment of diagnosis, adherence, and sleep.

Snapshot

Class: Adjunctive therapy
Common US brands: FOCALIN, FOCALIN XR
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-29

Label indications

Attention-deficit/hyperactivity disorder (ADHD).

View labelExact

Clinical Highlights

Dexmethylphenidate (brands Focalin and Focalin XR) is the d‑enantiomer of methylphenidate and is used as a first-line stimulant option for ADHD. In practice, it often achieves similar clinical effect at lower milligram doses than racemic methylphenidate. Like other stimulants, it can improve attention and reduce impulsivity, but it can also worsen anxiety, insomnia, irritability, mania, or psychosis in susceptible patients. These risks matter when ADHD is comorbid with serious mental illness.

Formulation selection drives day-to-day usability. Immediate-release dosing emphasizes flexibility (often BID), while extended-release supports once-daily morning dosing with less midday “wear off.”
Benefits are typically noticeable quickly, but safe prescribing relies on cautious titration, a functional target, and monitoring rather than escalating doses in response to subjective energy.
The compare view, dexmethylphenidate evidence feed, and dexmethylphenidate print page can support safe-use counseling and monitoring.

Dosing & Formulations

Immediate-release tablets are typically taken twice daily; extended- release capsules are usually once daily in the morning. Compared with methylphenidate, effective doses are often lower in milligrams; treat conversion as approximate and monitor clinical coverage rather than relying on a strict ratio.

Typical initiation is at a low dose with weekly titration. When adverse effects appear early (insomnia, appetite loss, anxiety), dose timing and formulation changes often help more than adding additional medications.
Typical daily doses are product- and age-dependent; labeled maximums vary by formulation (for many products, about 20 mg/day for immediate- release and 40 mg/day for extended-release).
Late-day dosing can worsen insomnia; when evening rebound occurs, longer delivery systems or earlier dosing are often considered rather than sedative stacking.
Maximum recommended dose depends on the specific product; labels specify maximums, and escalation beyond typical ranges usually prompts reassessment of diagnosis, adherence, and sleep.

Monitoring & Risks

Appetite and weight: weight/BMI and meal timing are commonly tracked, especially in younger patients or anyone already underweight. Sleep: delayed sleep onset is common; earlier dosing and limiting afternoon/evening doses are often used when feasible.

Cardiovascular: blood pressure and heart rate are commonly monitored, especially with hypertension, arrhythmia history, or other sympathomimetics.
Psychiatric activation: agitation, mood elevation, or hallucinations can emerge; suspected mania or psychosis typically prompts reassessment and often discontinuation.
Misuse/diversion: stimulants are controlled substances; counseling often covers locked storage, and substance use risk is typically assessed.

Drug Interactions

Contraindicated with MAO inhibitors; an adequate washout is required. Additive sympathomimetic effects can occur with decongestants and other stimulants; vital signs and anxiety symptoms are commonly monitored.

Alcohol can worsen impairment and may change release characteristics of some extended-release products; co-use is generally avoided.

Practice Notes

Titration is often anchored to function (work performance, task completion, driving safety) rather than “how energized” a patient feels. In patients with bipolar spectrum illness, psychosis vulnerability, or active substance use, non-stimulants are often considered; if stimulants are trialed, closer follow-up is typical.

When response is inconsistent across the day, formulation duration and dosing timing are often revisited before dose escalation.

References

Focalin (dexmethylphenidate HCl) prescribing information — DailyMed (2025)
Focalin XR (dexmethylphenidate HCL Extended Release) Prescribing Information — DailyMed (2025)
Attention deficit hyperactivity disorder (NICE guideline NG87) — NICE (2018)
Clinical Practice Guideline FOR THE Diagnosis, Evaluation, AND Treatment OF Attention Deficit/hyperactivity Disorder IN Children AND Adolescents — Pediatrics (2019)
Comparative Efficacy AND Tolerability OF Medications FOR Adhd (systematic Review AND Network Meta Analysis) — Lancet Psychiatry (2018)